FinnCap began coverage on shares of Shield Therapeutics (LON:STX) in a research note issued to investors on Tuesday, ThisIsMoney.Co.Uk reports. The brokerage issued a corporate rating and a GBX 200 ($2.61) price target on the stock.
STX has been the subject of several other reports. Peel Hunt restated a buy rating on shares of Shield Therapeutics in a research report on Wednesday, April 24th. Liberum Capital restated a buy rating on shares of Shield Therapeutics in a research report on Wednesday, April 3rd.
STX opened at GBX 100 ($1.31) on Tuesday. The firm has a market cap of $117.09 million and a PE ratio of -66.67. Shield Therapeutics has a 52-week low of GBX 24 ($0.31) and a 52-week high of GBX 100 ($1.31).
Shield Therapeutics Company Profile
Shield Therapeutics plc, a specialty pharmaceutical company, in the development and commercialization of hospital-focused pharmaceuticals to treat unmet medical needs. Its lead product is Feraccru, a novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease.
Featured Story: Purposes and Functions of the Federal Reserve
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.